… Conclusions: In summary, we report preclinical data on an orally bioavailable AR PROTAC
degrader, ARV-110, that demonstrates efficacy in multiple prostate cancer models. ARV-110 …

… of tumor growth. In summary, the AR PROTAC ARV-330 removes AR from prostate cancer
… efficacious therapy for patients with prostate cancer for whom current therapies have failed. …

… , the disease often progresses to castration-resistant prostate cancer (CRPC), which is still
… molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, …

… data on an orally bioavailable AR PROTAC degrader ARV-110 that demonstrates efficacy
in enzalutamideresistant prostate cancer. PROTAC: PROteolysis TArgeting Chimera …

… In order to induce AR degradation most effectively, a PROTAC AR degrader needs to
form a … restriction of the linker in an AR PROTAC degrader may lead to a more stable and …

… oral PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets AR…
, 2) AR L702H mutation or AR-V7 (variants not degraded by ARV-110 in nonclinical studies), …

… PROTAC degraders of androgen receptor (AR), as exemplified by compound 34 (ARD-69).
ARD-69 induces degradation of AR protein in AR-positive prostate cancer … + prostate cancer …

… a disease condition such as prostate cancer and Kennedy’s Disease. The first targeted protein
degrader (Arv-110, an orally bioavailable small molecule AR PROTAC) has been cleared …

… Background: Proteolysis Targeting Chimera (PROTAC) … PROTAC that specifically degrades
AR ≥ 95% and achieves anti-tumor activity in ENZ-naïve and -resistant prostate cancer …

This presentation contains forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, …